Send to a Friend Font Size: Increase Decrease

BMY and PHIL Related Headlines

Jun 10, 2025 05:57PM Philogen subsidiary and Bristol-Myers (BMY) subsidiary announce licensing agreement for OncoACP3
Jun 10, 2025 05:55PM Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Compan

BMY and PHIL Related Press Releases

Jun 10, 2025 05:55PM Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Compan

BMY and PHIL Related SEC Filings